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Me amount of trapped cells and their viability. There ware rm acute complications (death, 
tamponade. ventricular perforation, arrhythmia). Preliminary in vitro testing of cell viability 
after passage through the catheter yielded a 88.8 +/- 2.5% (mean +/- SEM) rate which 
was highly pressure-dependent. Following explantation, clusters of SM could be histolog- 
ically Identified by computerized assisted analysis in the anterior, apical and septal walls 
in the 8 hearts and represented 11 +/- 2.2% of the initial injectate. The viability of grafted 
SM retrieved from the transplanted area and assessed by a positive staining for CD 56 
averaged 3%. This percentage which might represent an underestimation due to injec- 
tion in non infracted myocardium, is still 10 fold higher than that previously observed after 
SM injections through an endovascular catheter. These preliminary data suggest that the 
CS mute could represent a safe and effective mean of percutaneous SM intramyocardial 
transfer but improvements in delivery systems remain mandatory to reduce physical train 
during lnjeotions and consequently optimise oelt survival. 
1176-199 Saff%y and Efficacy of Subcutaneous Enoxaparin in 
Early Invasive Strategy of Unstable Angina 
Jean-Philiooe Collet, Gilles Montalescot, Jean-Louis Golmard. M. Tanguy, Remi 
Choussat, GBrard Dmbinski, Annick Ankri. Nicolas Vignolles, Daniel Thomas, Piti& 
SalpBtriBrs, Paris, Francs 
Introduction : We have demonstrated previously that subcutaneous (s/c) enoxaparin 
(1 mg/Kg/l2h) given during at least 46 hours provided good anticoagulation and clinical 
results in non-ST elevation acute coronary syndromes (NBTE-ACS) patients undergoing 
percutaneous coronary intervention (PCI) within 8 hours of the last injection. We evalu- 
ated whether an early invasive (El) strategy with only 2 injections of s/c enoxaparin was 
as good as a delayed invasive (DI) strategy with 3 injections or more. 
Methods and results : We compared NSTE-ACS patients who underwent PCI after 2 
injections of s/c enoxaparin (El. n=ll7) with those referred later on (DI, 5.9i0.2 s/c injec- 
tions, n=230). Anti-Xa at the time of catheterization, safety and major coronary events 
(death/MI) were assessed at 30 days. Baseline characteristics were similar in the 2 
groups of patients. The period of medical stabilization was 20.5tl.O ha in the ‘El” and 
69.2i3.0 hrs in the “DI” group, respectively (~0.0001). The anti-Xa activity measured at 
the time of catheterization (0.92+0.04 tJ/mL vs 0.96+0.02 U/mL. ~0.25) and the injection 
to catheterization time (5.6kO.2 hrs. vs 5.2kO.l hrs, p=O.17) were similar in both groups. 
Patients of the “El” group were more frequently treated by IlWllla inhibitors and clopi- 
dogrel before PCI than patients of the “01” group (58.1% vs 31.7%, pcO.0001 for GPllbl 
llla inhibitors and 88.4% vs 40.4% for clopidogrel pretreatment, p<O.OOOl, respectively). 
Bleeding rates were found to be equivalent between both groups (1.7% vs 4.8%, for “El” 
and “Dl” strategies respectively, p=O.23, one-sided 95% Cl of 0.628). There was a non 
significant trend for less death or Ml at 30 days in the “El” group compared to the “DI” 
group (4.3% vs 7.0%, respectively, p=O.32, one-sided 95% Cl of 1.536). 
Conclusion: In patients with NSTE-ACS, a rapid invasive strategy with only 2 s/c injec- 
tions of snoxaparin provides similar levels of anticoaQulation and similar bleeding rates 
with a trend for less ischsmic major events as a more pmlonged “upstream“ treatment 
wfth enoxaparin. 
1176-197 Combination of a Direct Thrombin Inhibitor, Argatroban, 
and Glvcoorotein llb/llla Inhibitor Is Effective and Safe - . 
in Patients Undergoing Percutaneous Coronary 
Intervention 
Ik-Kvuna Jana, Bruce E. Lewis, William H. Matthai. Neal S. Kleiman, Massachusetts 
General Hospital. Boston, MA, Baylor College of Medicine, Houston, TX 
Background: Argatroban, a small molecule direct thrombin inhibitor, has been shown to 
block clot bound thrombin more effectivsly than does unfractionated heparin. Argatroban 
has not been systematically tested in patients undergoing percutaneous coronav inter- 
vention (PCI) with concurrent glycoprotein (GP) Ilb/llla. 
Methods: In this multicenter. prospective, pllot study argatroban was administered in 
patients undergoing PCI at 250 mcg/kg bolus followed by 15 mcglkglmin during the pro- 
cedure. Additional boluses of 150 mwIka were given, if ACT did not reach the taraet _ _ 
range of 275-326 sec. GP Ilb/llla inhibitor was administered simultaneously. The primary 
efficacy endpoint was vascular death, myocardial infarction (Ml), or urgent revasculadza- 
tion at 30 days. The safety endpoint was in-hospital major bleeding. MI was defined as 
CKMB elevation more than 3 times the upper llmlt of normal or cardiac symptoms with 
supportive cardiac marker or EKG evidence. 
Reauftaz A total of 101 patients were enrolled and completed the PCI procedure. There 
were 72 males and the mean age was 65 years. Abciiimab was given to 99 patients and 
double balus sptttihatide to 2 patients. 76 patients had one target lesion treated and the 
rest, two or more lesions. 96 patients were treated with stenting. Second and third 
boluses of argatroban were required in 22 and 7 patients, respectively. The target ACT 
was achieved in 94 patients. The primary efficacy endpoint occurred in 3 (3.0%) patients 
(no vascular death, 3 MIS and 2 urgent revascularizations). Two additlonal patients had 
cardiac symptoms and elevated troponin without significant CKMB elevation. There were 
2 major bleeding events (1 retroperitoneal, 1 groin hsmatoma). Conclusion:Argatroban 
in combination with GP Ilb/llla inhibitors provides adequate anticoagulation with accept- 
able bleeding risk. These data suggest that further investigation of argatroban in patients 
undergoing PCI is warmntad. 
1176-196 Unfractionatad Heparln Increases Platelet-Monocyte 
Binding In Vitro and in Patlents Undergoing 
Percutaneous Coronary Intervention 
Scull Hardinq, Debra H. Josephs. David E. Newby, Ian Drawfield, Chris Haslett, Keith A. 
A. Fox. Jaydssp Sanna, Royal Infirmary of Edinburgh, Edinburgh, Untied Kingdom 
Background: Unfractionated heparin is currently considered to he the anticoagulant of 
choice in patients undergoing percutaneous corona&! intervention (PCI). Unfractionated 
heparin may be associated with adverse platelet activation. Platelet-monwyte aggrega- 
tion (PMA) is a sensitive marker of platelet activation and may mediate pro-inflammatory 
cytokine release, tissue factor expression and augmented adhesion molecule expres- 
sion. We compared the effects of unfractionatsd hsparin, a low-molecular-weight-heparin 
(enoxaparin), and a direct thrombin inhibitor (lspirudin) on PMA In vitro. We also investi- 
gated the effects of unfractionated heparln on PMA in patients prior to PCI. 
Methods: Peripheral venous blood was collected frpm 18 healthy volunteers into sodium 
citrate alone or sodium citrate with unfractionated heparin (1 U/ml), enoxaparin (0.8 U/ml) 
or lepirudin (5.6pg/ml). Blood was also drawn into sodium citrate tubes from 14 patients 
immediately before and five minutes after administration of 100 U/kg of unfractionated 
hepartn, prior to elective PCI. PMA was determined by P-color flow-cytometric analysis. 
Reautta: In healthy vdunteers, PMA was higher in blood anticoagulated with sodium cti- 
rate and unfractionated hepadn (20.1 t 1.9%) compared to sodium citrate alone (16.2 * 
1.6%, p<o.OOl) or sodium citrate with enoxaparin (18.9 t 2.0%, p<O.Oi) or lepirudin 
(17.0 t 2.2%. wO.01). There were no differences In PMA in blood anticoagulated with 
sodium citrate alone, sodium citrate and enoxaparin. or sodium citrate and lepirudin 
(p=ns). Administration of unfractionated heparin to patients prior to PCI was also associ- 
ated with Increased PMA (24.2 f 2.6% vs. 16.9 f 2.4%, pcO.01). 
C~nclualona: In contrast to enoxaparin and lepirudin, unfractlonated heparin increases 
PMA in vitro: an effect that was also demonstrable in patients receiving unfractionated 
hsparin prior to PCI. Given that PMA is a sensitive measure of platelet activation and 
may have proinflammatory consequences, the use of alternative anticoagulant regimens 
may reduce PCI associated complications. 
1176-200 Ascressment of Anticoagulation Using Activated 
Clotting Times in Patients Receiving Intravenous 
Enoxaparin During Percutaneous Coronary Intervention 
Mark Lawrence, Tsnothv Mixon. Donald Cross, Gregory Dehmer, Scott and White Clinic, 
Temple, TX 
Background: Low molecular weight heparins have many advantages over unfraction- 
ated heparin. They have been used safely during percutaneous coronary intervention 
(PCI) when given intravenously (IV) with and without glycoprotein 2bl3a receptor inhibi- 
tors. lnterventionalists have been reluctant to use this therapy because of the inability to 
monitor the anticoagulant effect of IV enoxaparin. We measured activated clotting time 
(ACT), before and after IV enoxaparin, to determins if antlcoagulation could be assessed 
with this standard test. 
Methods: 45 consecutive patients undergoing PCI received either 0.75 mglkg IV enox- 
aparin if they also received epttfibatide, or 1 mg/kg IV enoxaparin if no eptifibatide was 
given. ACT was measured using the Hemochron device before and 5 minutes following 
IV enoxapadn administration. 
Results: After 0.75 mgikg enoxapartn, mean ACT increased from 132 f 31 set to 2072 
25 sec. (pcO.001). Afler 1 mgkg enoxapadn. ACT increased fmm 121 -+ 28 set to 2125 
32 sec. (pcO.001). The mean increase in ACT vatw was 74 -+ 20 set (range 47 to 132) in 
the 0.75 mgikg group (n=36) and 92 + 28 set (range 32 to 120) in the 1 mglkg group 
(n=9). None of the patients had transient abrupt closure, thmmbus formation, major 
bleeding or required urgent revascularization. 
Eawrparfn dsee (m@k& 
Conclusions: Intravenous enoxaparin at clinically relevant doses, increases ACT levels 
in patients undergoIng PCI with and without eptifibatide. These data suggest that ACT 
may be useful in the measurement of enoxapaiin anticoagulation. 
1176-201 A Randomized Comparison of Dalteparln Versus 
Unfractionated Heparin Durlng Percutaneous Coronary 
Interventions 
Madhu K. Nataraian. Graham A. Turpie, Dominic L. Race, James L. Velianou, Shamw R. 
Mehta, Rizwan Airal, David R. Goodhart, Jeffrey S. Ginsberg, McMaster University, 
Hamilton, ON, Canada 
Background: Low molecular weight heparins are widely used in patients with coronary 
artery disease but experience with them during percutaneous coronary interventions 
(PCI) is limited. The purpose of this study was to compare the safety and effiicy of the 
low molecular weight hepartn, dalteparin (Dan.) to unfractionated heparin (UFH). 
Methods: A single-centre, randomized, double-blind study of Dalt. versus UFH in patients 
undergoing PCI was carried out. All patients undergoing planned or ad-hoc PCI (exclud- 
ing emergency PCI post-thmmbolysis or for shock) were eligible. Randomization was 
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stratified according to planned GPllb/llla inhibitor use. Bolus Dalt. or UFH were 
administered via arterial sheath (100 units/kg alone or 70units/kg with planned GP) 
immediately prior to PCI. The primary endpoint was death, myocardial infarction (defined 
as CK-MB&?XULN). urgent CABGlPCl or need for bail-out GP) up to 24 hours post-pro- 
cedure. 
Results: A total of 321 (Dan. 160 (51 planned GP) vs UFH 161 (50 planned GP) patients 
were randomized. All randomized patients received the assigned drug and underwent 
PCI. Overall baseline characteristics were as follows: mean age 62.9 yrs. male gender 
70.4%. diabetes 25.5%. PCI post acute coronary syndrome 50.5%, stent 88.2%, multi- 
vessel 11.5%, ad-hoc PCI 27.1%, clopidogrel pretreatment 87%. The primary endpoint 
was reached in 21(13.1%) Dalt. and 22(13.7%) UFH patients (p=ns). There was one 
death in the Dalt. group due to guider dissection. Angiographic complications (abrupt clo- 
sure or new thrombus) occurred in 6 (3.8%) Dalt. YS 4(2.5%) UFH patients. There were 
two major bleeds, both in the UFH group. The primary composite plus rehospitalization 
at 30 days was 18.1% vs 16.1%, Dalt. vs UFH patients. Mean activated clotting time at 
30 minutes post bolus was 239s for Dalt. YS 345s for UFH. Mean anti-factor Xa levels 
were Dalt. 1.1 dmLvs UFH 0.8 u/mLat 30 minutes and Dalt.0.6 u/mLvs UFH 0.2 u/mL at 
4 hours post PCI. Conclusions: Dalt. appears to be a safe and effective alternative to 
UFH during PCI, either alone or in combination with IV GPllblllla inhibitors. Despite ele- 
vated anti-factor Xa levels at 4 hours, bleeding complications were not increased III the 
Dalt. group. 
1176-202 Tissue Factor Predicts Long-Term Outcome After 
Percutaneous Coronary Revaecularization 
Sophie Susen. Karine Sautiere, Christophe Zawadzki, Anne Bauters, Jean Dallongeville. 
Philippe Asseman, Christophe Bauters, Jean Marc Lablanche, Brigitte Jude, Eric Van 
Belle, Hapital Cardiologique, Lille, France, lnstitut Pasteur, Lille, France 
Background:Tissue factor (TF) induced upon inflammatory stimuli including C-reactive 
protein (CRP) could participate in the thrombus progression associated with plaque rup- 
ture. 
The aim of this study was to determine the predictive value of plasma levels of TF mea- 
sured immediately before percutaneous coronary revascularization (PCR). 
Methods:Plasma TF and hs CRP were prospectively measured in 175 consecutive 
patients before PCR. Patients with 1.5 nglmL were excluded. The primary endpoint was 
the composite of death, myocardial infarction and hospitalization for unstable angina at 
one year. Multivariate correlates of events were analyzed with the use of Cox’s propor- 
tional hazard model. Risk factors such as age, gender, diabetes. smoking status, family 
history of CAD, hypertension, hyperlypidemia, unstable angina, left ventricular ejection 
fraction, hs CRP and plasma TF were included in the analysis. 
Results: The mean +/- SD TF level was 205 +/- 169 pg/mL and the mean +/- SD hs CRP 
level was 0.8+/- 1.6 mg/dL. The actuarial rate of events was 9.7% at 1 year. Tertiles of 
TF were predictors of cardiac events at 1 year (see Table). 
Three independent predictors were found in this population: diabetes (p=O.O07), hs CRP 
(p=O.Ol) and plasma TF (p=O.O2). 
Conclusion: Plasma TF measured immediately before PCR is an independent predictor 
of cardiac events at 1 year. This suggests that measurement of TF may help to select 
patients at high risk of events following PCR. 
n events (%) 
tertile 1 (<I30 pg/mL) 60 1.7% 
tertile 2 59 8.5% 
terlile 3 (>POOpg/mL) 56 19.6% 
0.005 
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850-l Angiographic In-Stent Restenosis Patten Predicts 
Outcome After Gamma Vascular Brachytherapy 
Costantino 0. Costantini, Alexandra J. Lansky, Roxana Mehran, Kazuyuki Shirai, Maria 
Corral, Moses Tarawak, Teraza Conway, Brian Proctor, Ecaterina Cristea, George 
Dangas. Gregg W. Stone, Martin Leon, Cardiovascular Research Foundation, New York, 
NY 
Background: Angiographlc In-stent pattern (ISRP) is an important predictor of RS after 
conventional PCI. The prognostic value of ISRP after gamma VBT has not been defined. 
Methods : From a pooled data set of gamma VBT for ISR trials, the ISRP was assessed 
in 531 pts. Placebo (N=206) and radiated (N=327) pts were compared for angiographic 
recurrence based on the ISRP. The patterns are defined as focal (I), diffuse in stent (II), 
diffuse proliferative (Ill) or total occlusion (IV). 
Results Demographics were well matched between groups. Mean reference diameter 
(2.66kO.6 vs 2.67t0.5), lesion length (22.7ill.8 YS 21.2+11) and final MLD (1.99+0.4 vs 
1.95e 0.3) were similar (p=NS) between placebo and radiated patients. Angiographic RS 
rate increased with higher ISRP class for placebo (42.2%, 63.6%. 79.3%. 69.2%, 
p=O.O02) and radiated pts (l&7%, 31.6%, 43.1%. 80%, pcO.001) from I to IV, respec- 
tively (graphic). A treatment effect was maintained with Gamma VBT except for ISRP IV, 
where RS rate was not significantly different compared to placebo. By multivanable 
regression analysis, ISRP was an independent predictor of treated segment RS in both 
treatment groups. 
Conclusions : Angiographic classification of ISR is prognostically important independent 
of the treatment applied. Although a treatment effect is observed in class I, II and Ill, 
gamma radiation does not improve angiographic outcome in pattern IV compared to pla- 
cebo. ISRP continues to identify pts with higher probability of recurrence even after 
Gamma VBT. 
2:15 p.m. 
850-2 Five-Year Follov+Up After lntracoronary Gamma 
Radiation Therapy for In-Stent Restenosis: Results 
From a Randomized Clinical Trial 
Ron Waksman, Andrew E. Ajani, Larry R. White, Edward F. Cheneau, August0 D. 
Pichard, Lowell F. Satler, Kenneth M. Kent, Regina Deible, Verne Mattox, Ellen Pinnow. 
Peter Iloanya. Joseph Lindsay, Washington Hospital Center, Washington, DC 
Background:The Washington Radiation for In-Stent Restenosis Trial (WRIST) is a dou- 
ble-blinded randomized study evaluating the effects of intracoronary radiation therapy 
(IRT) in patients (pts) with in-stent restenosis (ISR). 
Methods: One hundred and thirty pts with ISR (100 native coronary and 30 vein grafts) 
underwent PTCA. laser ablation, rotational atherectomy, and/or additional stating (36% 
of lesions). Pts were randomized to either’92 II IRT. with a prescribed dose of 15 Gy to a 
2 mm radial distance from the center of the source or to placebo. 
Results: Angiographic restenosis (27% vs. 56%, p=O.O02) and target vessel revascular- 
ization (TVR. (26% vs. 66%, pcO.OOl)] were dramatically reduced at 6 months in IRT pts. 
Between 6 and 60 months, IRT pts compared to placebo had more target lesion revascu- 
larization (IRT=20% vs. placebo=l.5%. p=O.OOl) and TVR (IRT=20% vs. placebo=3%, 
p=O.O03). At 60 months clinical follow-up, pts receiving IRT continued to have markedly 
lower MACE (TLR) rates when compared with placebo: 51% vs.71%, p=O.O2 (see Fig- 
ure). 
Conclusions: In WRIST, pts with ISR treated with IRT using “‘lr had a marked reduc- 
tion in the need for repeat target lesion and vessel revascularization at 6 months. 
Although more events were recorded in the irradiated group at the follow-up 6-60 
months, the clinical benefit was maintained at five years without adverse events related 
to the radiation therapy 
